Virtual biopsy for prostate cancer using PSMA PET and AI

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The project combines early static and dynamic PSMA PET imaging with MRI, tracer kinetic modelling, and deep learning to predict tumor Gleason Score non-invasively. Imaging-derived biomarkers will be validated against ex-vivo cellular measures of PSMA internalization and conventional histopathology when available. The approach aims to provide full 3D assessment of the prostate and shorten diagnostic workflows. Data will be collected at a single center and used to train and validate predictive AI models.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* For patients who have undergone biopsies prior to PET:
* Patients referred to clinical PET examination
* For patients who have not had biopsies prior to PET:
* Patients referred to urologist for suspected prostate cancer based on clinical symptoms or elevated PSA-levels

Exclusion Criteria:

* Prostatektomy
* Body weight under 100 kg
* MRI incompatible implants or other incompatibilities

Where it's running

• Universitetssykehuset Nord Norge, Tromsø
  Tromsø, Troms, Norway Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 68Ga-XMFH01 PET/FL imaging to guide prostate cancer surgery

  This study tests a new dual-modality imaging probe, 68Ga-XMFH01, to preoperatively detect prostate cancer and guide the surgeon with fluorescence during operations in adults with newly diagnosed prostate cancer.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07885423

• Hugo Robotic Prostatectomy in an Ambulatory Surgery Center

  This study tests the use of the Hugo robotic system for prostate removal in adult men treated at an outpatient surgical center.

  Recruiting Central Ohio Urology Group · Columbus, Ohio · NCT07875192

• Adaptive intraoperative biopsy system for prostate cancer using imaging and metabolic feedback

  Aiming to test a smart biopsy approach that combines preoperative imaging with real-time metabolic signals to guide where to take prostate biopsy cores for better precision in men suspected of prostate cancer.

  Recruiting at 4 sites Shanghai Zhongshan Hospital · Shanghai and 3 other locations · NCT07856017

• miRNA panel test to help diagnose prostate cancer

  A blood test using a microRNA panel is being tested to help diagnose prostate cancer in men who are suspected of having the disease.

  Recruiting RenJi Hospital · Shanghai · NCT07755592

• Testing 68Ga-NYM032 PET/CT in men with newly diagnosed prostate cancer

  This study tests a new PSMA-targeted PET/CT imaging agent to see if it safely and accurately locates cancer in men who have just been diagnosed with prostate cancer and are planned for surgery.

  Recruiting at 2 sites Phase 3 Norroy Bioscience Co., LTD · Nanjing, Jiangsu and 1 other locations · NCT07615101

• Multi-Modal Imaging and Digital Pathology to Predict Clinically Significant Prostate Cancer

  A multi-center study tests a deep learning model that combines MRI, ultrasound, and digital pathology to see if it can predict clinically significant prostate cancer non-invasively and help guide biopsies.

  Recruiting Guangxi Medical University · Liuzhou, Guangxi · NCT07614256

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.